Corium ADLARITY PressRelease

Corium Receives FDA Approval of ADLARITY (donepezil transdermal system) for Treatment of Patients with alzheimer 's Disease First and only once-weekly patch for convenient, well-tolerated delivery of most used drug for treatment of alzheimer 's-related dementia First approved prescription drug using Corium 's proprietary CORPLEX . technology, used for years in consumer products Second CNS product approval for Corium in 12 months Boston, MA, March 14, 2022 Corium , Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the Food and Drug Administration (FDA) has approved Corium 's ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of the alzheimer 's type.

according to the World Health Organization. The U.S. Centers for Disease Control and Prevention estimates that in 2020, more than 11 million Americans provided an estimated 15.3 billion hours of unpaid care for patients with Alzheimer’s disease. About Corium Corium, Inc., is a commercial-stage biopharmaceutical company that is leading the

Loading..

Tags:

  World, Alzheimer

Information

Related search queries